Advanced

Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer

Micke, Patrick; Mattsson, Johanna Sofia Margareta; Edlund, Karolina; Lohr, Miriam; Jirström, Karin LU ; Berglund, Anders; Botling, Johan; Rahnenfuehrer, Joerg; Marincevic, Millaray and Ponten, Fredrik, et al. (2014) In International Journal of Cancer 135(9). p.2206-2214
Abstract
Claudins (CLDNs) are central components of tight junctions that regulate epithelial-cell barrier function and polarity. Altered CLDN expression patterns have been demonstrated in numerous cancer types and lineage-specific CLDNs have been proposed as therapy targets. The objective of this study was to assess which fraction of patients with non-small-cell lung cancer (NSCLC) express CLDN6 and CLDN18 isoform 2 (CLDN18.2). Protein expression of CLDN6 and CLDN18.2 was examined by immunohistochemistry on a tissue microarray (n=355) and transcript levels were supportively determined based on gene expression microarray data from fresh-frozen NSCLC tissues (n=196). Both were analyzed with regard to frequency, distribution and association with... (More)
Claudins (CLDNs) are central components of tight junctions that regulate epithelial-cell barrier function and polarity. Altered CLDN expression patterns have been demonstrated in numerous cancer types and lineage-specific CLDNs have been proposed as therapy targets. The objective of this study was to assess which fraction of patients with non-small-cell lung cancer (NSCLC) express CLDN6 and CLDN18 isoform 2 (CLDN18.2). Protein expression of CLDN6 and CLDN18.2 was examined by immunohistochemistry on a tissue microarray (n=355) and transcript levels were supportively determined based on gene expression microarray data from fresh-frozen NSCLC tissues (n=196). Both were analyzed with regard to frequency, distribution and association with clinical parameters. Immunohistochemical analysis of tissue sections revealed distinct membranous positivity of CLDN6 (6.5%) and CLDN18.2 (3.7%) proteins in virtually non-overlapping subgroups of adenocarcinomas and large-cell carcinomas. Pneumocytes and bronchial epithelial cells were consistently negative. Corresponding to the protein expression, in subsets of non-squamous lung carcinoma high mRNA levels of CLDN6 (7-16%) and total CLDN18 (5-12%) were observed. Protein expression correlated well with total mRNA expression of the corresponding gene (rho=0.4-0.8). CLDN18.2 positive tumors were enriched among slowly proliferating, thyroid transcription factor 1 (TTF-1)-negative adenocarcinomas, suggesting that isoform-specific CLDN expression may delineate a specific subtype. Noteworthy, high CLDN6 protein expression was associated with worse prognosis in lung adenocarcinoma in the univariate [hazard ratio (HR): 1.8; p=0.03] and multivariate COX regression model (HR: 1.9; p=0.02). These findings encourage further clinical exploration of targeting ectopically activated CLDN expression as a valuable treatment concept in NSCLC. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
non-small-cell lung cancer, targeted therapy, gene expression profiling, claudin, tissue microarray
in
International Journal of Cancer
volume
135
issue
9
pages
2206 - 2214
publisher
John Wiley & Sons
external identifiers
  • wos:000341983700026
  • scopus:84906278734
ISSN
0020-7136
DOI
10.1002/ijc.28857
language
English
LU publication?
yes
id
86c353dc-6c96-4192-bdb7-4ef407b54bfb (old id 4699664)
date added to LUP
2014-11-03 07:20:56
date last changed
2017-08-27 03:24:58
@article{86c353dc-6c96-4192-bdb7-4ef407b54bfb,
  abstract     = {Claudins (CLDNs) are central components of tight junctions that regulate epithelial-cell barrier function and polarity. Altered CLDN expression patterns have been demonstrated in numerous cancer types and lineage-specific CLDNs have been proposed as therapy targets. The objective of this study was to assess which fraction of patients with non-small-cell lung cancer (NSCLC) express CLDN6 and CLDN18 isoform 2 (CLDN18.2). Protein expression of CLDN6 and CLDN18.2 was examined by immunohistochemistry on a tissue microarray (n=355) and transcript levels were supportively determined based on gene expression microarray data from fresh-frozen NSCLC tissues (n=196). Both were analyzed with regard to frequency, distribution and association with clinical parameters. Immunohistochemical analysis of tissue sections revealed distinct membranous positivity of CLDN6 (6.5%) and CLDN18.2 (3.7%) proteins in virtually non-overlapping subgroups of adenocarcinomas and large-cell carcinomas. Pneumocytes and bronchial epithelial cells were consistently negative. Corresponding to the protein expression, in subsets of non-squamous lung carcinoma high mRNA levels of CLDN6 (7-16%) and total CLDN18 (5-12%) were observed. Protein expression correlated well with total mRNA expression of the corresponding gene (rho=0.4-0.8). CLDN18.2 positive tumors were enriched among slowly proliferating, thyroid transcription factor 1 (TTF-1)-negative adenocarcinomas, suggesting that isoform-specific CLDN expression may delineate a specific subtype. Noteworthy, high CLDN6 protein expression was associated with worse prognosis in lung adenocarcinoma in the univariate [hazard ratio (HR): 1.8; p=0.03] and multivariate COX regression model (HR: 1.9; p=0.02). These findings encourage further clinical exploration of targeting ectopically activated CLDN expression as a valuable treatment concept in NSCLC.},
  author       = {Micke, Patrick and Mattsson, Johanna Sofia Margareta and Edlund, Karolina and Lohr, Miriam and Jirström, Karin and Berglund, Anders and Botling, Johan and Rahnenfuehrer, Joerg and Marincevic, Millaray and Ponten, Fredrik and Ekman, Simon and Hengstler, Jan and Woell, Stefan and Sahin, Ugur and Tuereci, Oezlem},
  issn         = {0020-7136},
  keyword      = {non-small-cell lung cancer,targeted therapy,gene expression profiling,claudin,tissue microarray},
  language     = {eng},
  number       = {9},
  pages        = {2206--2214},
  publisher    = {John Wiley & Sons},
  series       = {International Journal of Cancer},
  title        = {Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer},
  url          = {http://dx.doi.org/10.1002/ijc.28857},
  volume       = {135},
  year         = {2014},
}